Gonadorelin
Synthetic gonadotropin-releasing hormone that sits at the very top of the reproductive axis, driving pulsatile pituitary LH and FSH release.
Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), a ten-amino-acid decapeptide identical in sequence to the hypothalamic hormone that controls the entire hypothalamic-pituitary-gonadal (HPG) axis. Delivered in a pulsatile pattern it stimulates pituitary release of LH and FSH, restoring gonadotropin secretion in hypothalamic hypogonadism and inducing ovulation in hypothalamic amenorrhea. It was historically FDA-approved as Factrel (diagnostic pituitary testing) and Lutrepulse (pulsatile ovulation induction), and is now widely used off-label in men's health as an alternative to hCG for maintaining testicular function during testosterone replacement therapy. Its defining constraint is a plasma half-life of only a few minutes, meaning delivery pattern is critical: pulsatile dosing stimulates the axis while continuous exposure paradoxically suppresses it.
Class
Synthetic decapeptide (native gonadotropin-releasing hormone)
Half-life
~2-10 minutes in plasma
Routes
Subcutaneous, Intravenous, Intranasal, Pulsatile pump infusion
Category
Hormone & Reproductive
Researched benefits
What it's studied for
Pulsatile LH and FSH stimulation
As native GnRH, gonadorelin binds pituitary gonadotroph GNRHR receptors to trigger release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This is core, established pharmacology and the foundation of every downstream reproductive-hormone signal.
Testicular function maintenance during TRT
Exogenous testosterone suppresses endogenous LH via negative feedback, causing testicular atrophy and reduced intratesticular testosterone. Pulsatile gonadorelin aims to preserve gonadotroph responsiveness and Leydig-Sertoli cell function, though evidence for this specific off-label application is weaker than for hCG.
Fertility preservation via intact FSH pathway
Because gonadorelin acts at the pituitary rather than directly at the testis, it preserves FSH stimulation of spermatogenesis alongside LH-driven testosterone. The extrapolation from pump-based fertility protocols to bolus TRT self-injection is not backed by randomized trials.
Ovulation induction in hypothalamic amenorrhea
Pulsatile pump-delivered gonadorelin is an established first-line ovulation-induction strategy, achieving high ovulation rates (roughly 70-90% in appropriately selected women) with essentially zero multiple-gestation risk because the physiologic pulse preserves natural follicle selection.
HPG axis restoration in hypogonadotropic hypogonadism
In congenital hypogonadotropic hypogonadism, pulsatile GnRH pump therapy increases testicular volume, serum testosterone, and can induce spermatogenesis, restoring the full physiologic axis in a way downstream agents cannot.
PCT and axis-restart support
In post-cycle protocols after anabolic suppression, gonadorelin is combined with agents such as enclomiphene and hCG to help reactivate endogenous LH/FSH signaling during HPG axis recovery.
Diagnostic pituitary evaluation
A single IV bolus with timed LH/FSH measurement was the classical GnRH stimulation test to distinguish hypothalamic from pituitary causes of gonadotropin deficiency, the original approved Factrel indication (now largely obsolete).
Mechanism
How it works
Gonadorelin acts exclusively through GnRH receptor 1 (GNRHR), a Gaq/11-coupled G-protein-coupled receptor densely expressed on anterior pituitary gonadotroph cells. Receptor binding activates phospholipase C-beta, generating IP3 and diacylglycerol; IP3 mobilizes intracellular calcium while DAG activates protein kinase C. Acute calcium flux triggers exocytosis of pre-formed gonadotropin granules, while downstream ERK1/2 and p38 MAPK signaling drives transcription of the gonadotropin subunit genes (CGA, LHB, FSHB). The result is release of LH and FSH, which act on the testes (Leydig-cell testosterone production and Sertoli-cell spermatogenesis) or ovaries (follicular development, ovulation, corpus luteum formation).
The single most important principle of gonadorelin pharmacology is that pulsatile versus continuous exposure produces opposite biological effects. Work by Knobil's group at Pittsburgh (Belchetz et al., 1978) showed that lesioned rhesus monkeys recovered normal cyclic gonadotropin release only when GnRH was delivered in pulses roughly every 60 minutes, not under continuous infusion. Pulsatile GnRH (every 60-120 minutes) stimulates and maintains fertility, whereas continuous high-level exposure causes rapid GNRHR desensitization, internalization, and downregulation, effectively shutting down gonadotropin release. This paradox is the basis for using long-acting GnRH agonists (leuprolide, goserelin, triptorelin) as chemical castration therapy in prostate cancer and precocious puberty.
Gonadorelin acts upstream of the pituitary and therefore requires functional gonadotrophs to work. This contrasts with hCG, a placental glycoprotein that acts directly on the testicular LHCGR receptor, bypassing the pituitary entirely and maintaining testicular function even when the pituitary axis is profoundly suppressed. Gonadorelin also sits one step downstream of kisspeptin, which stimulates the hypothalamic GnRH neurons that release native GnRH. This positioning makes gonadorelin biologically the closest to physiologic endogenous stimulation among axis-support agents, but also dependent on intact pituitary function.
Pharmacokinetically, gonadorelin has no oral bioavailability and requires parenteral delivery. Its plasma half-life is only 2-10 minutes owing to rapid proteolytic degradation by prolyl endopeptidase, post-proline cleaving enzymes, and neutral endopeptidase, with clearance primarily via renal and hepatic enzymatic degradation. A single subcutaneous bolus produces one peak within 10-20 minutes and returns to baseline within 45-60 minutes. This ultrashort half-life is the compound's defining practical limitation: it is why the original fertility indication required pulsatile pump delivery, and why community every-other-day injection schedules cannot faithfully reproduce the physiologic 60-120 minute pulse pattern.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Gonadorelin acetate lyophilized powder (commonly 2 mg or 10 mg vials). A 2 mg vial with 2 mL bacteriostatic water yields 1 mg/mL (1,000 mcg/mL), so a 100 mcg dose is 0.1 mL (10 units on an insulin syringe); alternatively 2 mg in 5 mL BAC water yields 0.4 mg/mL (100 mcg = 0.25 mL / 25 units). A 10 mg vial in 5 mL BAC water yields 2 mg/mL (100 mcg = 0.05 mL / 5 units). Inject BAC water slowly down the vial wall, swirl gently (never shake), and wait 2-3 minutes for a clear solution. Refrigerate after reconstitution; BAC-water solutions are stable at 2-8C for ~28 days, sterile-water single-dose for 24-48 hours. Never freeze; protect from light.
Beginner (TRT adjunct)
- Dose
- 100 mcg
- Frequency
- 2x per week
- Timing
- Evening (e.g. Monday and Thursday), to align with nocturnal GnRH pulses
- Duration
- 12 weeks initial evaluation
- Route
- Subcutaneous
Conservative starting point during TRT to help maintain testicular size and function. Rotate injection sites; reassess testicular volume, symptoms and labs at month 3.
Intermediate (axis optimization)
- Dose
- 100 mcg (3x weekly) or 200 mcg (2x weekly), or 100 mcg every other day
- Frequency
- 3x weekly / 2x weekly / every other day depending on option
- Timing
- Consistent timing; evening dosing may better mimic physiologic patterns
- Duration
- Weeks 13-24
- Route
- Subcutaneous
Higher frequency more closely approximates physiologic pulse frequency; every-other-day is the most physiologic pattern achievable without a pump. A hybrid option adds hCG 250 IU SC on alternate days for direct testicular stimulation.
Advanced (PCT / axis restart)
- Dose
- 200 mcg, tapering to 100 mcg
- Frequency
- 3x weekly, tapering to 2x weekly
- Timing
- Combined regimen across a staged 12+ week taper
- Duration
- 4-12+ weeks
- Route
- Subcutaneous
Combined with enclomiphene (25 mg -> 12.5 mg daily) and hCG 500 IU 2x weekly in staged phases to restart the HPG axis after anabolic suppression. Best done with endocrinology or urology oversight; LH/FSH typically detectable within 2-4 weeks.
Pulsatile pump (specialist only)
- Dose
- 5-25 mcg per pulse
- Frequency
- Every 60-120 minutes
- Timing
- Continuous programmed pulsatile delivery
- Duration
- Titrated to LH response and clinical effect
- Route
- Programmable mini-pump (SC or IV)
The evidence-based physiologic replacement for hypogonadotropic hypogonadism and ovulation induction (5-10 mcg every 60-90 min in women). Requires a Lutrepulse-type device and reproductive endocrinology management.
Diagnostic (historical)
- Dose
- 100 mcg
- Frequency
- Single bolus
- Timing
- Measure LH/FSH at 0, 30, 45, 60 minutes
- Duration
- Single test
- Route
- Intravenous
The classical GnRH stimulation test to distinguish hypothalamic from pituitary gonadotropin deficiency; largely obsolete, replaced by baseline panels and imaging.
- Frequency matters as much as total dose because of the ultrashort half-life: 2-3x weekly intermittent pulses approximate physiology, less frequent may allow axis suppression to progress, and daily or continuous exposure risks paradoxical receptor desensitization.
- The 100 mcg starting dose reflects a practical consensus: enough to produce an LH response in most users, below typical adverse-event thresholds, and convenient dilution math (1 mg/mL, 0.1 mL, ~20 doses per 2 mg vial).
- None of the community TRT-adjunct doses have been validated against placebo or hCG in randomized trials; if fertility preservation is the actual goal, hCG (e.g. 500 IU twice weekly) has substantially stronger clinical evidence.
- Baseline and follow-up monitoring should include total and free testosterone, LH, FSH, sensitive estradiol, SHBG, CBC/CMP, PSA (men 40+), plus semen analysis and testicular volume when fertility is a goal.
- For any chronic-use scenario, pharmaceutical-grade compounded material with USP/third-party COA testing is strongly preferable to grey-market research-chemical sourcing.
- Women's fertility and puberty-induction applications require pump-based protocols under reproductive endocrinology supervision and are not appropriate for DIY bolus dosing.
Evidence
Research & clinical studies (3)
Therapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogonadism: a retrospective study
In 54 adult men with congenital hypogonadotropic hypogonadism, pulsatile gonadorelin pump therapy significantly increased testicular volume, serum testosterone, and penile length at 6, 12, and 24 months, with 27 of 45 patients followed beyond 6 months producing spermatozoa and better outcomes in younger men and those with normal olfaction.
PMID 40800099Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis
Across 35 studies and 1,002 women with hypothalamic amenorrhea, pulsatile gonadorelin achieved high ovulation rates with a trend toward high pregnancy and live birth rates, low OHSS incidence, and low multiple gestation rates, establishing it as an effective and safe first-line ovulation induction strategy.
PMID 29605411Effect of post-insemination GnRH analogue administration on pregnancy rates in repeat-breeder cows: comparison of dosage and frequency
Administering a GnRH analogue during the early luteal phase after insemination improved pregnancy outcomes in repeat-breeder cows by increasing corpus luteum formation and reducing pregnancy loss, with both elevated-dose protocols similarly effective.
PMID 42091524Combinations
Stacking & blends
Gonadorelin + hCG Hybrid
Dual-level testicular support during TRT
Gonadorelin maintains pituitary gonadotroph signaling while hCG provides direct Leydig-cell (LHCGR) stimulation, covering both the pituitary and the testis; combination is theoretical with no trial evidence but is used for comprehensive axis support.
PCT Axis-Restart Stack
Restart endogenous HPG axis after suppression
Enclomiphene blocks estrogen-mediated negative feedback to raise endogenous GnRH drive, gonadorelin directly stimulates gonadotroph LH/FSH release, and hCG maintains testicular output during the recovery window.
Comprehensive Men's Health Protocol
Combined HPG and GH axis plus tissue-repair optimization
Gonadorelin maintains the reproductive axis during TRT while GH secretagogues (sermorelin or CJC-1295 + ipamorelin) support the somatotropic axis and BPC-157 supports joint/tissue maintenance; the axes are distinct and generally compatible.
Melanotan II + Gonadorelin
Central and hormonal sexual health support
Melanotan II drives centrally mediated arousal via MC3R/MC4R melanocortin pathways while gonadorelin provides hormonal baseline support through pulsatile LH/FSH stimulation of the HPG axis (preclinical rationale).
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Known hypersensitivity to gonadorelin or any GnRH analog
- Hormone-sensitive cancers (prostate, breast) without oncology consultation
- Active gonadotroph adenoma (functional pituitary tumor)
- Severe primary hypogonadism / testicular failure where no response is possible (e.g. Klinefelter with complete failure)
- Pregnancy outside explicit specialist-supervised fertility protocols
- Continuous or high-frequency high-dose exposure (causes paradoxical receptor downregulation and suppression)
- Concurrent GnRH agonists (leuprolide, goserelin) or antagonists (cetrorelix, ganirelix) - opposing/antagonistic effects
- Caution with pituitary surgery/radiation history, severe renal or hepatic impairment, severe mood disorders, and uncontrolled hypertension
Gonadorelin has an extensive clinical safety record; because it is native GnRH with a very short half-life, side effects are generally milder than with sustained GnRH analogs, and decades of pump-based use show no established patterns of cancer or cardiovascular harm. The principal pharmacologic hazard is delivery pattern: sustained high-level or continuous exposure can desensitize the pituitary within 1-3 weeks and shut down testosterone the same way leuprolide (Lupron) does, though intermittent every-2-4-day bolus dosing allows receptor recovery between doses. Long-term safety of the newer off-label bolus TRT-adjunct use is not characterized by dedicated longitudinal studies, and sourcing quality is itself a chronic-use safety consideration.
FAQ
Gonadorelin — common questions
What is gonadorelin and how does it work?
Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), a ten-amino-acid peptide identical to the native hypothalamic hormone. It binds pituitary GnRH receptors to stimulate LH and FSH release, which in turn drive testicular testosterone production and spermatogenesis in men or ovarian follicular development and ovulation in women. It must be given in a pulsatile pattern to stimulate the axis rather than suppress it.
How is gonadorelin different from hCG?
Gonadorelin acts one step upstream at the pituitary GnRH receptor and requires intact pituitary function, whereas hCG is a placental glycoprotein that acts directly on the testicular LH receptor, bypassing the pituitary entirely. Gonadorelin produces a more physiologic pattern and preserves the full axis including FSH-driven spermatogenesis, but hCG has decades of stronger clinical evidence for testicular preservation and can work even when the pituitary is fully suppressed.
Does gonadorelin actually preserve fertility on TRT?
It's uncertain. The specific bolus protocol used in TRT (roughly 100-300 mcg SC every 2-4 days) has essentially no prospective randomized trial evidence for fertility endpoints, and extrapolating from pump-delivered pulsatile GnRH is a large leap because the pulse patterns differ dramatically. It may help testicular size and comfort, but for true fertility preservation hCG (e.g. 500 IU twice weekly) is the better-evidenced choice.
Can gonadorelin shut down testosterone like Lupron?
Yes, this is a real theoretical risk with high-frequency or high-dose regimens. Continuous GnRH receptor exposure causes desensitization and downregulation - the exact mechanism that makes leuprolide effective for chemical castration. Intermittent every-2-4-day bolus dosing is unlikely to cause sustained suppression because receptor expression recovers between doses, but daily or continuous dosing risks the same paradoxical shutdown.
What is a reasonable gonadorelin dose for TRT support?
Community protocols most commonly use 100-300 mcg subcutaneously 2-3 times per week, with 100 mcg twice weekly as a conservative starting point and 200-300 mcg every 3-4 days as a more aggressive regimen. Because of the short half-life, dosing frequency matters as much as total dose. None of these have been validated against placebo or hCG in trials.
Is gonadorelin FDA-approved and legal?
It was FDA-approved as Factrel (diagnostic) and Lutrepulse (pulsatile ovulation induction), both withdrawn from the US market for commercial rather than safety reasons; the currently visible US Factrel label is veterinary. Compounded gonadorelin is available through US 503A/503B pharmacies by prescription, and research-grade material is sold for laboratory use, but its TRT and PCT uses are off-label.
Is gonadorelin the same as sermorelin?
No. Gonadorelin is GnRH and drives the reproductive axis (LH/FSH, testosterone/estrogen, gametogenesis), while sermorelin is GHRH and drives the growth-hormone axis (GH, IGF-1, body composition). Both act at the pituitary and share pulsatile physiology, but they target different cells and receptors and produce entirely different effects - the shared suffix is coincidental.
Can women use gonadorelin?
Yes, in specific contexts. Pump-delivered pulsatile gonadorelin (about 5-10 mcg every 60-90 minutes) is established for ovulation induction in hypothalamic amenorrhea and for puberty induction in GnRH-deficient adolescents, with ovulation rates around 70-90% and near-zero multiple-pregnancy risk. Bolus self-injection for non-specific 'hormone optimization' lacks evidence and can disrupt normal cyclicity; women should work with a reproductive endocrinologist using validated pump protocols.
